Haematology Strong — Greenberg 2012 / IPSS-R consensus
IPSS-R for Myelodysplastic Syndrome
Revised International Prognostic Scoring System for MDS. Predicts overall survival and AML transformation risk.
References
- Greenberg PL et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- Alendronic Acid (Alendronate) · Bisphosphonate (bone resorption inhibitor)
- Pramipexole (Restless Legs Syndrome — Elderly) · Dopamine Agonist (D2/D3 Receptor)
- Azacitidine · Hypomethylating Agent — MDS / AML
- Teriparatide · Parathyroid Hormone Analogue (Anabolic Bone Agent)
- Denosumab · Anti-RANKL Monoclonal Antibody
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.